Case Challenges in nAMD and DME Management: Achieving Durable Response

The management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has provided enhanced visual outcomes for many patients. However, the high treatment burden associated with anti-VEGF therapies can lead to lack of patient adherence, resulting in suboptimal outcomes. Personalized treatment protocols using FDA-approved agents and newer novel delivery systems, along with agents with unique mechanisms of action, have been developed to address the treatment burden by extending the interval between dosing of treatment while providing visual acuity gains. In this case-based CE and COPE activity, experts in the field evaluate treatment protocols that offer increased efficacy, safety, and durability in patients with nAMD and DME and provide guidance for practices and procedures that can improve patient adherence to therapeutic regimens.